NOV 16, 2017 9:00 AM PST

WEBINAR: Breaking Bad with 3D: The development of high throughput screening platforms to interrogate physiologically relevant models

Sponsored by: PerkinElmer
Speaker
  • Lead, Trans-NIH RNAi Facility Division of Pre-Clinical Innovation National Center for Advancing Translational Sciences National Institutes of Health
    BIOGRAPHY

Abstract

DATE: November 16, 2017
TIME: 9:00AM PT, 12:00PM ET

The wide use of 2D monolayer cultures for cancer drug discovery reflects the technical ease of implementation for drug screening, and the view that oncogenes or tumor suppressor genes are the key genetic drivers of cancer cell proliferation, and therefore, inhibiting these tumor driver genes with drugs should prevent tumor growth.   However, there is now ample evidence that the cellular and physiological context in which these oncogenic events occur play a key role in how they drive tumor growth in vivo, and therefore, in how a tumor responds to drug treatments. In vitro three dimensional (3D) spheroid cell culture tumor models are being developed to potentially enhance the predictability and efficiency of drug discovery in cancer.  Furthermore, the insight that primary tumors are vastly different from their metastatic counterparts has necessitated a paradigm shift in the development of HTS screening models to efficiently recapitulate key components of primary and metastatic disease. The ability to increase the throughout for a 3D spheroid assays will enable the generation of pharmacological profiles of chemotherapeutic agents and will hopefully illustrate more effective therapies that might have been missed in 2D, and deprioritize treatments options that might have looked very potent in 2D but have not efficacy in 3D.  This approach to cell biology has the potential to improve the physiological relevance of cell-based assays and advance the quantitative modeling of biological systems from cells to organisms.

 Learning Objecives:

  • Application of 3D models within oncology research and therapeutic strategies
  • Why scaling 3D models to a higher throughput format is important for higher throughput screening of drug candidates
  • Comparison of mechanism of action data from 3D models to that generated from 2D systems

 


Show Resources
You May Also Like
NOV 16, 2022 7:00 PM PST
C.E. CREDITS
NOV 16, 2022 7:00 PM PST
Date: November 16, 2022 Time: 2:00pm (AEST) Date: November 17, 2022 7:00pm (PST), 10:00pm (EST), 4:00am (CET) The growth in FDA-approved cell and gene therapy products for the treatment of d...
MAY 17, 2022 9:00 AM PDT
MAY 17, 2022 9:00 AM PDT
Date: May 17, 2022 Time: 9:00am (PDT), 12:00pm (EDT), 8:00pm (CEST) Gene therapeutics have great potential to treat many severe diseases in an unprecedented, targeted manner. The biopharmace...
SEP 22, 2022 9:00 AM PDT
SEP 22, 2022 9:00 AM PDT
Date: September 22, 2022 Time: 9:00am (PDT), 12:00pm (EDT), 6:00pm (CEST) Optimizing platforms for surgical specimen collection and deep human phenotyping was used to enhance protein biomarke...
APR 26, 2022 7:00 AM PDT
C.E. CREDITS
APR 26, 2022 7:00 AM PDT
Date: April 19, 2022 Time: 7:00am (PDT), 10:00am (EDT), 4:00pm (CEST) High-content (HC) phenotypic profiling approaches are a powerful tool to study the effect of biological, genetic, and ch...
NOV 09, 2022 8:00 AM PST
NOV 09, 2022 8:00 AM PST
Date: November 09, 2022 Time: 8:00am (PST), 11:00am (EST), 5:00pm (CET) The field of cell and gene therapy is rapidly growing. In particular, the use of lentiviruses in CAR-T applications is...
AUG 10, 2022 10:00 AM PDT
AUG 10, 2022 10:00 AM PDT
Date: August 10, 2022 Time: 10:00am PDT, 1:00pm EDT The global pandemic has increased focus and scrutiny on molecular diagnostic assay development, resulting in a need for assays that provid...
NOV 16, 2017 9:00 AM PST

WEBINAR: Breaking Bad with 3D: The development of high throughput screening platforms to interrogate physiologically relevant models

Sponsored by: PerkinElmer


Show Resources
Loading Comments...
Show Resources